Oligonucleotide analogs having cationic intersubunit linkages

(19)

(11)

EP 2 735 568 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	27.09.2017 Bulletin 2017/39

(45)	Mention of the grant of the patent:
	02.08.2017 Bulletin 2017/31

(21)	Application number: 13186973.7

(22)	Date of filing: 10.05.2007

(51)

International Patent Classification (IPC):

C07H 21/00^(2006.01)
C07H 19/16^(2006.01)

C12N 15/11^(2006.01)
C07H 19/20^(2006.01)

(54)	Oligonucleotide analogs having cationic intersubunit linkages Oligonucleotid-analoge mit kationischen Zwischenuntereinheitsverknüpfungen Analogues d'oligonucléotides ayant des liaisons internes de sous-unités cationiques

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30)

Priority:

10.05.2006 US 432216
10.05.2006 US 432031
10.05.2006 US 432155
10.05.2006 US 431968
11.05.2006 US 433257
11.05.2006 US 799976 P
11.05.2006 US 800145 P
11.05.2006 US 433213
11.05.2006 US 433214
11.05.2006 US 433033
11.05.2006 US 433840
11.05.2006 US 433724
11.05.2006 US 800076 P
11.05.2006 US 800120 P
08.09.2006 US 518058
08.09.2006 US 517757
08.11.2006 US 595161
07.03.2007 US 715572

(43)	Date of publication of application:
	28.05.2014 Bulletin 2014/22

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	07861308.0 / 2024499

(73)	Proprietor: Sarepta Therapeutics, Inc.
	Cambridge, MA 02142 (US)

(72)	Inventors:
	Weller, Dwight D. Corvallis, OR 97330 (US) Hassinger, Jed N. Philomath, OR 97370 (US) Cai, Bao Corvallis, OK 97330 (US)

(74)	Representative: D Young & Co LLP
	120 Holborn London EC1N 2DY London EC1N 2DY (GB)

(56)

References cited: :

US-A- 5 185 444

SUMMERTON ET AL: "Morpholino antisense oligomers: design, preparation, and properties", SENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 7, 1 January 1997 (1997-01-01), pages 187-195, XP002136176, ISSN: 1087-2906

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).